Zenas BioPharma, Inc. — Form SCHEDULE 13D/A
Filed August 17, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 22/100
What the filing says
SR One Capital Management, LLC and affiliated funds (SR One Capital Fund II Aggregator LP, SR One Capital Partners I & II LPs, SR One Capital Opportunities Fund I LP, and multiple co-invest entities), all controlled by Dr. Simeon George, executed an agreement on August 17, 2026 to file a single joint Schedule 13D with respect to their combined ownership of Zenas BioPharma shares. The filing documents a power of attorney granting Sasha Keough, Karen Narolewski-Engel, James Macadam, and Alexander M. Bowling authority to execute SEC filings on behalf of the filers.
Why this rating
Administrative Schedule 13D amendment documenting aggregated disclosure arrangement; no specific shareholding amounts, % ownership, or transactions disclosed; routine securities reporting compliance filing.
See more from August 17, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.